Targeting IGF-1R: throwing out the baby with the bathwater?
作者信息
Basu B, Olmos D, de Bono J S
出版信息
Br J Cancer. 2011 Jan 4;104(1):1-3. doi: 10.1038/sj.bjc.6606023.
Abstract
摘要
相似文献
1
Targeting IGF-1R: throwing out the baby with the bathwater?
Br J Cancer. 2011 Jan 4;104(1):1-3. doi: 10.1038/sj.bjc.6606023.
2
Insulin-like growth factor receptor inhibitors: baby or the bathwater?
J Natl Cancer Inst. 2012 Jul 3;104(13):975-81. doi: 10.1093/jnci/djs258.
3
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer.
Expert Opin Investig Drugs. 2010 May;19(5):631-9. doi: 10.1517/13543781003767434.
4
Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1179-87. doi: 10.1016/j.ijrobp.2010.10.003. Epub 2010 Dec 2.
5
Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
Sci Rep. 2016 Aug 4;6:31072. doi: 10.1038/srep31072.
6
Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
Clin Cancer Res. 2009 Aug 15;15(16):5117-25. doi: 10.1158/1078-0432.CCR-09-0478. Epub 2009 Aug 11.
7
[Targeting insulin-like growth factors in the treatment of cancer].
Rev Mal Respir. 2010 Oct;27(8):959-63. doi: 10.1016/j.rmr.2010.07.005. Epub 2010 Sep 17.
8
Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Cancer Lett. 2015 Jun 1;361(2):197-206. doi: 10.1016/j.canlet.2015.02.038. Epub 2015 Feb 23.
9
Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer.
Clin Lung Cancer. 2009 Jul;10(4):273-80. doi: 10.3816/CLC.2009.n.038.
10
Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer.
J Huazhong Univ Sci Technolog Med Sci. 2015 Dec;35(6):834-841. doi: 10.1007/s11596-015-1515-1. Epub 2015 Dec 16.
引用本文的文献
1
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12.
2
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Cancer Sci. 2017 Jul;108(7):1368-1377. doi: 10.1111/cas.13266. Epub 2017 Jun 19.
3
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Int J Cancer. 2017 Jul 15;141(2):383-392. doi: 10.1002/ijc.30715. Epub 2017 May 10.
4
Combine and conquer: challenges for targeted therapy combinations in early phase trials.
Nat Rev Clin Oncol. 2017 Jan;14(1):57-66. doi: 10.1038/nrclinonc.2016.96. Epub 2016 Jul 5.
5
Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.
Front Oncol. 2015 Jul 8;5:142. doi: 10.3389/fonc.2015.00142. eCollection 2015.
6
Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.
J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53. doi: 10.1007/s00432-014-1787-z. Epub 2014 Aug 1.
7
Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly.
Curr Oncol Rep. 2014 Sep;16(9):401. doi: 10.1007/s11912-014-0401-5.
8
Theranostic applications of antibodies in oncology.
Mol Oncol. 2014 Jun;8(4):799-812. doi: 10.1016/j.molonc.2014.03.010. Epub 2014 Mar 21.
9
Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
PLoS One. 2013 Jun 24;8(6):e66963. doi: 10.1371/journal.pone.0066963. Print 2013.
10
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Ann Oncol. 2013 Mar;24(3):784-91. doi: 10.1093/annonc/mds511. Epub 2012 Oct 26.
本文引用的文献
1
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
Br J Cancer. 2011 Jan 4;104(1):68-74. doi: 10.1038/sj.bjc.6605972. Epub 2010 Nov 23.
2
Targeting insulin-like growth factor signaling: rational combination strategies.
Mol Cancer Ther. 2010 Sep;9(9):2447-9. doi: 10.1158/1535-7163.MCT-10-0719. Epub 2010 Aug 31.
3
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.
Clin Cancer Res. 2010 Sep 15;16(18):4654-65. doi: 10.1158/1078-0432.CCR-10-0089. Epub 2010 Jul 29.
4
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13.
5
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8. doi: 10.1073/pnas.0914076107. Epub 2010 May 10.
6
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Lancet Oncol. 2010 Feb;11(2):129-35. doi: 10.1016/S1470-2045(09)70354-7. Epub 2009 Dec 23.
7
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.
J Thorac Oncol. 2009 Nov;4(11):1397-403. doi: 10.1097/JTO.0b013e3181ba2f1d.
8
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
9
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
J Clin Oncol. 2009 May 20;27(15):2516-22. doi: 10.1200/JCO.2008.19.9331. Epub 2009 Apr 20.
10
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.
J Clin Oncol. 2008 Jul 1;26(19):3196-203. doi: 10.1200/JCO.2007.15.9319. Epub 2008 May 12.
Zotero 插件